MARK RANDALL DENISON
Medical Practice in Nashville, TN
License number
Pennsylvania MD038034E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Nashville, TN 37212
Pennsylvania
Pennsylvania
Professional information
Mark Denison, Nashville TN
Work:
VCH Medical Staff Office
2200 Childrens Way, Nashville, TN 37232 Vanderbilt Pediatric Endcrnlgy
3601 The Vanderbilt Clinic, Nashville, TN 37232
2200 Childrens Way, Nashville, TN 37232 Vanderbilt Pediatric Endcrnlgy
3601 The Vanderbilt Clinic, Nashville, TN 37232
Dr. Mark Denison, Nashville TN - MD (Doctor of Medicine)
Specialties:
Pediatric Infectious Disease Medicine
Address:
Vanderbilt Childrens Inf Diseas
2200 Childrens Way STE 9102-DOT, Nashville 37232
(615) 322-2250 (Phone)
2200 Childrens Way STE 9102-DOT, Nashville 37232
(615) 322-2250 (Phone)
Certifications:
Pediatric Infectious Disease Medicine, 2002, Pediatrics, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Vanderbilt Childrens Inf Diseas
2200 Childrens Way STE 9102-DOT, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
2200 Childrens Way STE 9102-DOT, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
Education:
Medical School
University of Kansas / School of Medicine
Graduated: 1980
University Of Iowa Hospitals & Clinics
University of Kansas / School of Medicine
Graduated: 1980
University Of Iowa Hospitals & Clinics
Live Attenuated Nidovirus Vaccines
US Patent:
2007028, Dec 13, 2007
Filed:
Apr 22, 2004
Appl. No.:
10/553883
Inventors:
Mark Denison - Nashville TN, US
Assignee:
Vanderbilt University - Nashville TN
International Classification:
A61K 39/12, A61K 35/76, A61P 31/00
US Classification:
424204100, 424093600
Abstract:
The present invention is directed live, attenuated Nidovirus vaccines, and in a particular embodiment, to coronavirus vaccines. The vaccine comprises a viral genome encoding a replicase polyprotein having at least one proteinase cleavage site that exhibits reduced or no cleavage. Such viruses show reduced.
Live Attenuated Coronavirus Vaccines
US Patent:
7452542, Nov 18, 2008
Filed:
May 23, 2005
Appl. No.:
11/135603
Inventors:
Mark Denison - Nashville TN, US
Assignee:
Vanderbilt University - Nashville TN
International Classification:
A61K 39/215, C12N 7/00, C12N 7/04, C12N 15/50
US Classification:
4242211, 4352351, 435236, 536 2372
Abstract:
The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.